{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:16Z","timestamp":1781176336190,"version":"3.54.1"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02074-x","type":"journal-article","created":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T07:01:12Z","timestamp":1687071672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current advances in microbial-based cancer therapies"],"prefix":"10.1007","volume":"40","author":[{"given":"Areej","family":"Shahbaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehreem","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Uzair","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6529-2134","authenticated-orcid":false,"given":"Bilal Haider","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,18]]},"reference":[{"issue":"1","key":"2074_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2074_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4161\/bbug.1.3.10903","volume":"1","author":"N Bernardes","year":"2010","unstructured":"Bernardes N, Seruca R, Chakrabarty AM, Fialho AM. Microbial-based therapy of cancer: current progress and future prospects. Bioeng Bugs. 2010;1(3):178\u201390. https:\/\/doi.org\/10.4161\/bbug.1.3.10903.","journal-title":"Bioeng Bugs."},{"key":"2074_CR3","volume-title":"Pathophysiology-e-book: the biologic basis for disease in adults and children","author":"KL McCance","year":"2018","unstructured":"McCance KL, Huether SE. Pathophysiology-e-book: the biologic basis for disease in adults and children. Amsterdam: Elsevier Health Sciences; 2018."},{"key":"2074_CR4","volume-title":"Oral radiology-e-book: principles and interpretation","author":"SC White","year":"2014","unstructured":"White SC, Pharoah MJ. Oral radiology-e-book: principles and interpretation. Amsterdam: Elsevier Health Sciences; 2014."},{"issue":"4","key":"2074_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271\u201389.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2074_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3322\/caac.21398","volume":"67","author":"AP Bhatt","year":"2017","unstructured":"Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67(4):326\u201344. https:\/\/doi.org\/10.3322\/caac.21398.","journal-title":"CA Cancer J Clin"},{"key":"2074_CR7","doi-asserted-by":"publisher","first-page":"100436","DOI":"10.1016\/j.ctarc.2021.100436","volume":"28","author":"H Ji","year":"2021","unstructured":"Ji H, Yang X. Microbial-based cancer therapy\u2014bugs as drugs: history & the essential role of medical imaging. Cancer Treat Res Commun. 2021;28:100436.","journal-title":"Cancer Treat Res Commun"},{"issue":"7","key":"2074_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/cgt.2011.10","volume":"18","author":"S Ganai","year":"2011","unstructured":"Ganai S, et al. In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther. 2011;18(7):457\u201366. https:\/\/doi.org\/10.1038\/cgt.2011.10.","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"2074_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrc1367","volume":"4","author":"JM Brown","year":"2004","unstructured":"Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437\u201347.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2074_CR10","doi-asserted-by":"publisher","first-page":"e1398875","DOI":"10.1080\/2162402X.2017.1398875","volume":"7","author":"M Bazett","year":"2018","unstructured":"Bazett M, et al. Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy. Oncoimmunology. 2018;7(3):e1398875. https:\/\/doi.org\/10.1080\/2162402X.2017.1398875.","journal-title":"Oncoimmunology."},{"key":"2074_CR11","doi-asserted-by":"publisher","first-page":"197675","DOI":"10.1016\/j.virusres.2019.197675","volume":"270","author":"L-Q Fu","year":"2019","unstructured":"Fu L-Q, et al. Recent advances in oncolytic virus-based cancer therapy. Virus Res. 2019;270:197675. https:\/\/doi.org\/10.1016\/j.virusres.2019.197675.","journal-title":"Virus Res"},{"key":"2074_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cytogfr.2020.07.005","volume":"56","author":"MF Leber","year":"2020","unstructured":"Leber MF, et al. Engineering and combining oncolytic measles virus for cancer therapy. Cytokine Growth Factor Rev. 2020;56:39\u201348. https:\/\/doi.org\/10.1016\/j.cytogfr.2020.07.005.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"2074_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0381-3","volume":"6","author":"NS Forbes","year":"2018","unstructured":"Forbes NS, et al. White paper on microbial anti-cancer therapy and prevention. J Immunother Cancer. 2018;6(1):1\u201324. https:\/\/doi.org\/10.1186\/s40425-018-0381-3.","journal-title":"J Immunother Cancer"},{"issue":"6230","key":"2074_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.aaa4972","volume":"348","author":"WS Garrett","year":"2015","unstructured":"Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80\u20136. https:\/\/doi.org\/10.1126\/science.aaa4972.","journal-title":"Science"},{"issue":"11","key":"2074_CR15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nrc3610","volume":"13","author":"RF Schwabe","year":"2013","unstructured":"Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800\u201312. https:\/\/doi.org\/10.1038\/nrc3610.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2074_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/bjc.2015.465","volume":"114","author":"E Vogtmann","year":"2016","unstructured":"Vogtmann E, Goedert JJ. Epidemiologic studies of the human microbiome and cancer. Br J Cancer. 2016;114(3):237\u201342. https:\/\/doi.org\/10.1038\/bjc.2015.465.","journal-title":"Br J Cancer"},{"key":"2074_CR17","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.09.001","author":"SJ Bultman","year":"2016","unstructured":"Bultman SJ. The microbiome and its potential as a cancer preventive intervention. Semin Oncol. 2016. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.001.","journal-title":"Semin Oncol"},{"issue":"1","key":"2074_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bpg.2016.02.009","volume":"30","author":"P Ambalam","year":"2016","unstructured":"Ambalam P, et al. Probiotics, prebiotics and colorectal cancer prevention. Best Prac Res Clin Gastroenterol. 2016;30(1):119\u201331. https:\/\/doi.org\/10.1016\/j.bpg.2016.02.009.","journal-title":"Best Prac Res Clin Gastroenterol"},{"issue":"8","key":"2074_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrmicro.2017.44","volume":"15","author":"L Zitvogel","year":"2017","unstructured":"Zitvogel L, et al. Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017;15(8):465\u201378. https:\/\/doi.org\/10.1038\/nrmicro.2017.44.","journal-title":"Nat Rev Microbiol"},{"issue":"6371","key":"2074_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science"},{"key":"2074_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fonc.2018.00136","volume":"8","author":"S Kaimala","year":"2018","unstructured":"Kaimala S, et al. Attenuated bacteria as immunotherapeutic tools for cancer treatment. Front Oncol. 2018;8:136. https:\/\/doi.org\/10.3389\/fonc.2018.00136.","journal-title":"Front Oncol"},{"issue":"1","key":"2074_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/10942912.2018.1448994","volume":"21","author":"SS Malik","year":"2018","unstructured":"Malik SS, et al. Anticarcinogenecity of microbiota and probiotics in breast cancer. Int J Food Prop. 2018;21(1):655\u201366. https:\/\/doi.org\/10.1080\/10942912.2018.1448994.","journal-title":"Int J Food Prop"},{"issue":"7","key":"2074_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41568-019-0155-3","volume":"19","author":"E Elinav","year":"2019","unstructured":"Elinav E, et al. The cancer microbiome. Nat Rev Cancer. 2019;19(7):371\u20136. https:\/\/doi.org\/10.1038\/s41568-019-0155-3.","journal-title":"Nat Rev Cancer"},{"issue":"938","key":"2074_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/postgradmedj\/79.938.672","volume":"79","author":"SH Cann","year":"2003","unstructured":"Cann SH, Van Netten J, Van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J. 2003;79(938):672\u201380.","journal-title":"Postgrad Med J"},{"issue":"3","key":"2074_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.biotechadv.2018.02.005","volume":"36","author":"V Luginbuehl","year":"2018","unstructured":"Luginbuehl V, et al. Intracellular drug delivery: potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy. Biotechnol Adv. 2018;36(3):613\u201323. https:\/\/doi.org\/10.1016\/j.biotechadv.2018.02.005.","journal-title":"Biotechnol Adv"},{"key":"2074_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2016.09.007","volume":"106","author":"Z Hosseinidoust","year":"2016","unstructured":"Hosseinidoust Z, et al. Bioengineered and biohybrid bacteria-based systems for drug delivery. Adv Drug Deliv Rev. 2016;106:27\u201344. https:\/\/doi.org\/10.1016\/j.addr.2016.09.007.","journal-title":"Adv Drug Deliv Rev"},{"key":"2074_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cyto.2016.01.002","volume":"89","author":"SC Nallar","year":"2017","unstructured":"Nallar SC, Xu D-Q, Kalvakolanu DV. Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges. Cytokine. 2017;89:160\u201372. https:\/\/doi.org\/10.1016\/j.cyto.2016.01.002.","journal-title":"Cytokine"},{"issue":"1","key":"2074_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1158\/1940-6207.CAPR-15-0406","volume":"9","author":"TW Kensler","year":"2016","unstructured":"Kensler TW, et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res. 2016;9(1):2\u201310. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-15-0406.","journal-title":"Cancer Prev Res"},{"issue":"1","key":"2074_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep00436","volume":"2","author":"B Yu","year":"2012","unstructured":"Yu B, et al. Explicit hypoxia targeting with tumor suppression by creating an \u201cobligate\u201d anaerobic Salmonella typhimurium strain. Sci Rep. 2012;2(1):1\u201310. https:\/\/doi.org\/10.1038\/srep00436.","journal-title":"Sci Rep"},{"issue":"3","key":"2074_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1073\/pnas.0408422102","volume":"102","author":"M Zhao","year":"2005","unstructured":"Zhao M, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Nat Acad Sci. 2005;102(3):755\u201360. https:\/\/doi.org\/10.1073\/pnas.0408422102.","journal-title":"Proc Nat Acad Sci."},{"issue":"3","key":"2074_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4068\/cmj.2016.52.3.173","volume":"52","author":"JH Zheng","year":"2016","unstructured":"Zheng JH, Min J-J. Targeted cancer therapy using engineered Salmonella typhimurium. Chonnam Med J. 2016;52(3):173\u201384. https:\/\/doi.org\/10.4068\/cmj.2016.52.3.173.","journal-title":"Chonnam Med J"},{"key":"2074_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40588-019-00132-5","volume":"6","author":"KM Broadway","year":"2019","unstructured":"Broadway KM, Scharf BE. Salmonella typhimurium as an anticancer therapy: recent advances and perspectives. Curr Clin Microbiol Rep. 2019;6:225\u201339. https:\/\/doi.org\/10.1007\/s40588-019-00132-5.","journal-title":"Curr Clin Microbiol Rep"},{"issue":"24","key":"2074_CR33","doi-asserted-by":"publisher","first-page":"e2202719119","DOI":"10.1073\/pnas.2202719119","volume":"119","author":"SG Ahmed","year":"2022","unstructured":"Ahmed SG, et al. Intratumoral injection of schwannoma with attenuated Salmonella typhimurium induces antitumor immunity and controls tumor growth. Proc Nat Acad Sci. 2022;119(24):e2202719119. https:\/\/doi.org\/10.1073\/pnas.2202719119.","journal-title":"Proc Nat Acad Sci."},{"key":"2074_CR34","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s11999-008-0243-2","volume":"466","author":"BS Sorenson","year":"2008","unstructured":"Sorenson BS, et al. Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma. Clin Orthop Relat Res. 2008;466:1285\u201391. https:\/\/doi.org\/10.1007\/s11999-008-0243-2.","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"2074_CR35","doi-asserted-by":"publisher","first-page":"e34214","DOI":"10.1371\/journal.pone.0034214","volume":"7","author":"S Jellbauer","year":"2012","unstructured":"Jellbauer S, et al. CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma. PLoS ONE. 2012;7(4):e34214. https:\/\/doi.org\/10.1371\/journal.pone.0034214.","journal-title":"PLoS ONE"},{"issue":"1","key":"2074_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/1751-7915.12153","volume":"8","author":"B Mesa-Pereira","year":"2015","unstructured":"Mesa-Pereira B, et al. Improved cytotoxic effects of Salmonella-producing cytosine deaminase in tumour cells. Microb Biotechnol. 2015;8(1):169\u201376. https:\/\/doi.org\/10.1111\/1751-7915.12153.","journal-title":"Microb Biotechnol"},{"issue":"376","key":"2074_CR37","doi-asserted-by":"publisher","first-page":"aak9537","DOI":"10.1126\/scitranslmed.aak9537","volume":"9","author":"JH Zheng","year":"2017","unstructured":"Zheng JH, et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med. 2017;9(376):aak9537. https:\/\/doi.org\/10.1126\/scitranslmed.aak9537.","journal-title":"Sci Transl Med."},{"key":"2074_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fcimb.2014.00048","volume":"4","author":"F Carvalho","year":"2014","unstructured":"Carvalho F, Sousa S, Cabanes D. How Listeria monocytogenes organizes its surface for virulence. Front Cell Infect Microbiol. 2014;4:48. https:\/\/doi.org\/10.3389\/fcimb.2014.00048.","journal-title":"Front Cell Infect Microbiol"},{"key":"2074_CR39","doi-asserted-by":"publisher","first-page":"121332","DOI":"10.1016\/j.biomaterials.2021.121332","volume":"281","author":"Z Yang","year":"2022","unstructured":"Yang Z, et al. Engineering bioluminescent bacteria to boost photodynamic therapy and systemic anti-tumor immunity for synergistic cancer treatment. Biomaterials. 2022;281:121332. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121332.","journal-title":"Biomaterials"},{"issue":"24","key":"2074_CR40","doi-asserted-by":"publisher","first-page":"8821","DOI":"10.1158\/0008-5472.CAN-04-1958","volume":"64","author":"DA Sewell","year":"2004","unstructured":"Sewell DA, et al. Recombinant listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res. 2004;64(24):8821\u20135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1958.","journal-title":"Cancer Res"},{"issue":"38","key":"2074_CR41","doi-asserted-by":"publisher","first-page":"13832","DOI":"10.1073\/pnas.0406035101","volume":"101","author":"DG Brockstedt","year":"2004","unstructured":"Brockstedt DG, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Nat Aca Sci. 2004;101(38):13832\u20137. https:\/\/doi.org\/10.1073\/pnas.0406035101.","journal-title":"Proc Nat Aca Sci"},{"issue":"249","key":"2074_CR42","doi-asserted-by":"publisher","first-page":"249ra111","DOI":"10.1126\/scitranslmed.3008982","volume":"6","author":"NJ Roberts","year":"2014","unstructured":"Roberts NJ, et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med. 2014;6(249):249ra111. https:\/\/doi.org\/10.1126\/scitranslmed.3008982.","journal-title":"Sci Transl Med."},{"issue":"11","key":"2074_CR43","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/lary.21141","volume":"120","author":"N Ohta","year":"2010","unstructured":"Ohta N, et al. Treatments of various otolaryngological cystic diseases by OK-432 1: its indications and limitations. Laryngoscope. 2010;120(11):2193\u20136. https:\/\/doi.org\/10.1002\/lary.21141.","journal-title":"Laryngoscope"},{"issue":"11","key":"2074_CR44","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3109\/00016489.2010.483480","volume":"130","author":"N Ohta","year":"2010","unstructured":"Ohta N, et al. Effects and mechanism of OK-432 therapy in various neck cystic lesions. Acta Oto-laryngol. 2010;130(11):1287\u201392. https:\/\/doi.org\/10.3109\/00016489.2010.483480.","journal-title":"Acta Oto-laryngol"},{"key":"2074_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1590\/1806-9282.66.S2.91","volume":"66","author":"O Karabay","year":"2020","unstructured":"Karabay O, et al. Investigation of the frequency of COVID-19 in patients treated with intravesical BCG. Rev Assoc Med Bras. 2020;66:91\u20135. https:\/\/doi.org\/10.1590\/1806-9282.66.S2.91.","journal-title":"Rev Assoc Med Bras"},{"issue":"12","key":"2074_CR46","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1128\/IAI.71.12.6754-6765.2003","volume":"71","author":"IJ Glomski","year":"2003","unstructured":"Glomski IJ, Decatur AL, Portnoy DA. Listeria monocytogenes mutants that fail to compartmentalize listerolysin O activity are cytotoxic, avirulent, and unable to evade host extracellular defenses. Infect Immun. 2003;71(12):6754\u201365. https:\/\/doi.org\/10.1128\/IAI.71.12.6754-6765.2003.","journal-title":"Infect Immun"},{"issue":"11","key":"2074_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/gt.2017.74","volume":"24","author":"L Wang","year":"2017","unstructured":"Wang L, et al. Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo. Gene Ther. 2017;24(11):699\u2013705. https:\/\/doi.org\/10.1038\/gt.2017.74.","journal-title":"Gene Ther"},{"issue":"3","key":"2074_CR48","doi-asserted-by":"publisher","first-page":"193","DOI":"10.15171\/bi.2017.22","volume":"7","author":"A Asoudeh-Fard","year":"2017","unstructured":"Asoudeh-Fard A, et al. Lactobacillus plantarum induces apoptosis in oral cancer KB cells through upregulation of PTEN and downregulation of MAPK signalling pathways. Bioimpacts. 2017;7(3):193. https:\/\/doi.org\/10.15171\/bi.2017.22.","journal-title":"Bioimpacts"},{"key":"2074_CR49","doi-asserted-by":"publisher","first-page":"173596","DOI":"10.1016\/j.ejphar.2020.173596","volume":"887","author":"Y Shimizu","year":"2020","unstructured":"Shimizu Y, et al. Anti-tumor effect of a recombinant Bifidobacterium strain secreting a claudin-targeting molecule in a mouse breast cancer model. Eur J Pharmacol. 2020;887:173596. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173596.","journal-title":"Eur J Pharmacol"},{"issue":"3\u20134","key":"2074_CR50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1089\/hum.2020.271","volume":"32","author":"J Cai","year":"2021","unstructured":"Cai J, Yan G. The identification and development of a novel oncolytic virus: alphavirus M1. Hum Gene Ther. 2021;32(3\u20134):138\u201349. https:\/\/doi.org\/10.1089\/hum.2020.271.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"2074_CR51","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/cancers12051295","volume":"12","author":"M Sato-Dahlman","year":"2020","unstructured":"Sato-Dahlman M, LaRocca CJ, Yanagiba C, Yamamoto M. Adenovirus and immunotherapy: advancing cancer treatment by combination. Cancers (Basel). 2020;12(5):1295. https:\/\/doi.org\/10.3390\/cancers12051295.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2074_CR52","first-page":"4273","volume":"62","author":"YS Haviv","year":"2002","unstructured":"Haviv YS, et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res. 2002;62(15):4273\u201381.","journal-title":"Cancer Res"},{"issue":"6","key":"2074_CR53","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/jgm.223","volume":"3","author":"E Davison","year":"2001","unstructured":"Davison E, et al. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by \u03b1v\u03b21 integrin and can be modulated by changes in \u03b21 integrin function. J Gene Med. 2001;3(6):550\u20139. https:\/\/doi.org\/10.1002\/jgm.223.","journal-title":"J Gene Med"},{"issue":"9255","key":"2074_CR54","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(00)04048-4","volume":"357","author":"RM MacKie","year":"2001","unstructured":"MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet. 2001;357(9255):525\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(00)04048-4.","journal-title":"Lancet"},{"issue":"9","key":"2074_CR55","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm0995-938","volume":"1","author":"T Mineta","year":"1995","unstructured":"Mineta T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1(9):938\u201343. https:\/\/doi.org\/10.1038\/nm0995-938.","journal-title":"Nat Med"},{"issue":"2","key":"2074_CR56","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/mt.2008.240","volume":"17","author":"Y Fong","year":"2009","unstructured":"Fong Y, et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther. 2009;17(2):389\u201394. https:\/\/doi.org\/10.1038\/mt.2008.240.","journal-title":"Mol Ther"},{"key":"2074_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144619","author":"S Nair","year":"2021","unstructured":"Nair S, et al. Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/jci.insight.144619.","journal-title":"JCI Insight"},{"issue":"3","key":"2074_CR58","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/cancers13030544","volume":"13","author":"CE Engeland","year":"2021","unstructured":"Engeland CE, Ungerechts G. Measles virus as an oncolytic immunotherapy. Cancers. 2021;13(3):544. https:\/\/doi.org\/10.3390\/cancers13030544.","journal-title":"Cancers"},{"issue":"23","key":"2074_CR59","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1158\/1078-0432.CCR-09-1292","volume":"15","author":"EK Mader","year":"2009","unstructured":"Mader EK, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy modelvirotherapy in immune mice using MSC cell carriers. Clin Cancer Res. 2009;15(23):7246\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1292.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2074_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5516-5","volume":"19","author":"J Raihan","year":"2019","unstructured":"Raihan J, et al. Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines. BMC Cancer. 2019;19(1):1\u201313. https:\/\/doi.org\/10.1186\/s12885-019-5516-5.","journal-title":"BMC Cancer"},{"issue":"8","key":"2074_CR61","first-page":"1514","volume":"8","author":"T Ye","year":"2018","unstructured":"Ye T, et al. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. Am J Cancer Res. 2018;8(8):1514.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2074_CR62","doi-asserted-by":"publisher","first-page":"284","DOI":"10.14218\/JCTH.2021.00284","volume":"10","author":"L Chen","year":"2022","unstructured":"Chen L, et al. Oncolytic activity of wild-type Newcastle disease virus HK84 against hepatocellular carcinoma associated with activation of type I interferon signaling. J Clin Transl Hepatol. 2022;10(2):284. https:\/\/doi.org\/10.14218\/JCTH.2021.00284.","journal-title":"J Clin Transl Hepatol"},{"issue":"1\u20132","key":"2074_CR63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41434-021-00256-8","volume":"30","author":"L Tian","year":"2023","unstructured":"Tian L, et al. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy. Gene Ther. 2023;30(1\u20132):64\u201374. https:\/\/doi.org\/10.1038\/s41434-021-00256-8.","journal-title":"Gene Ther"},{"key":"2074_CR64","doi-asserted-by":"publisher","unstructured":"Ali SM, et al. In vivo oncolytic activity of non-virulent newcastle disease virus Iraqi strain against mouse mammary adenocarcinoma. In AIP Conference proceedings. 2021. https:\/\/doi.org\/10.1063\/5.0067194","DOI":"10.1063\/5.0067194"},{"key":"2074_CR65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s13337-020-00612-z","volume":"31","author":"AG Al-Ziaydi","year":"2020","unstructured":"Al-Ziaydi AG, et al. Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death. Virusdisease. 2020;31:341\u20138. https:\/\/doi.org\/10.1007\/s13337-020-00612-z.","journal-title":"Virusdisease."},{"key":"2074_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-8-47","volume":"8","author":"S Sei","year":"2009","unstructured":"Sei S, et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer. 2009;8:1\u201315. https:\/\/doi.org\/10.1186\/1476-4598-8-47.","journal-title":"Mol Cancer"},{"issue":"2","key":"2074_CR67","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/v15020523","volume":"15","author":"C-Y Hsu","year":"2023","unstructured":"Hsu C-Y, et al. Oncolytic avian reovirus \u03c3A-modulated upregulation of the HIF-1\u03b1\/C-myc\/glut1 pathway to produce more energy in different cancer cell lines benefiting virus replication. Viruses. 2023;15(2):523. https:\/\/doi.org\/10.3390\/v15020523.","journal-title":"Viruses"},{"issue":"21","key":"2074_CR68","doi-asserted-by":"publisher","first-page":"9991","DOI":"10.1158\/0008-5472.CAN-05-1630","volume":"65","author":"ZS Guo","year":"2005","unstructured":"Guo ZS, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. 2005;65(21):9991\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1630.","journal-title":"Cancer Res"},{"issue":"12","key":"2074_CR69","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3390\/vaccines9121497","volume":"9","author":"KH Gupta","year":"2005","unstructured":"Gupta KH, Nowicki C, Giurini EF, Marzo AL, Zloza A. Bacterial-based cancer therapy (BBCT): recent advances, current challenges, and future prospects for cancer immunotherapy. Vaccines 2021;9(12):1497","journal-title":"Vaccines"},{"issue":"3","key":"2074_CR70","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ejca.2006.10.005","volume":"43","author":"MQ Wei","year":"2007","unstructured":"Wei MQ, et al. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J cancer. 2007;43(3):490\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2006.10.005.","journal-title":"Eur J cancer"},{"issue":"1","key":"2074_CR71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","volume":"14","author":"UE Martinez-Outschoorn","year":"2017","unstructured":"Martinez-Outschoorn UE, et al. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11\u201331. https:\/\/doi.org\/10.1038\/nrclinonc.2016.60.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2074_CR72","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrc2934","volume":"10","author":"NS Forbes","year":"2010","unstructured":"Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010;10(11):785\u201394. https:\/\/doi.org\/10.1038\/nrc2934.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2074_CR73","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1002\/cam4.2148","volume":"8","author":"M Sedighi","year":"2019","unstructured":"Sedighi M, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. Cancer Med. 2019;8(6):3167\u201381. https:\/\/doi.org\/10.1002\/cam4.2148.","journal-title":"Cancer Med"},{"issue":"26","key":"2074_CR74","doi-asserted-by":"publisher","first-page":"14748","DOI":"10.1073\/pnas.261606598","volume":"98","author":"RK Jain","year":"2001","unstructured":"Jain RK, Forbes NS. Can engineered bacteria help control cancer? Proc Nat Acad Sci. 2001;98(26):14748\u201350. https:\/\/doi.org\/10.1073\/pnas.261606598.","journal-title":"Proc Nat Acad Sci."},{"issue":"10","key":"2074_CR75","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.4155\/tde.13.94","volume":"4","author":"R Carlisle","year":"2013","unstructured":"Carlisle R, Coussios C-C. Mechanical approaches to oncological drug delivery. Ther Deliv. 2013;4(10):1213\u20135. https:\/\/doi.org\/10.4155\/tde.13.94.","journal-title":"Ther Deliv"},{"issue":"7","key":"2074_CR76","first-page":"1408","volume":"58","author":"JM Brown","year":"1998","unstructured":"Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58(7):1408\u201316.","journal-title":"Cancer Res"},{"issue":"3","key":"2074_CR77","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/gt.2008.188","volume":"16","author":"R Ryan","year":"2009","unstructured":"Ryan R, et al. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther. 2009;16(3):329\u201339. https:\/\/doi.org\/10.1038\/gt.2008.188.","journal-title":"Gene Ther"},{"key":"2074_CR78","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0076-6879(09)65013-8","volume":"465","author":"I Cheong","year":"2009","unstructured":"Cheong I, Zhou S. Tumor-specific liposomal drug release mediated by liposomase. Meth Enzymol. 2009;465:251\u201365. https:\/\/doi.org\/10.1016\/S0076-6879(09)65013-8.","journal-title":"Meth Enzymol"},{"issue":"9","key":"2074_CR79","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1128\/JB.185.9.2683-2686.2003","volume":"185","author":"A Chakrabarty","year":"2003","unstructured":"Chakrabarty A. Microorganisms and cancer: quest for a therapy. J Bacteriol. 2003;185(9):2683\u20136. https:\/\/doi.org\/10.1128\/JB.185.9.2683-2686.2003.","journal-title":"J Bacteriol"},{"issue":"1","key":"2074_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13027-018-0180-y","volume":"13","author":"S Song","year":"2018","unstructured":"Song S, Vuai MS, Zhong M. The role of bacteria in cancer therapy\u2013enemies in the past, but allies at present. Infect Agents Cancer. 2018;13(1):1\u20137. https:\/\/doi.org\/10.1186\/s13027-018-0180-y.","journal-title":"Infect Agents Cancer"},{"issue":"1","key":"2074_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep03394","volume":"3","author":"SJ Park","year":"2013","unstructured":"Park SJ, et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep. 2013;3(1):1\u20138. https:\/\/doi.org\/10.1038\/srep03394.","journal-title":"Sci Rep"},{"key":"2074_CR82","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.snb.2015.09.034","volume":"224","author":"J-W Han","year":"2016","unstructured":"Han J-W, et al. Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella typhimurium). Sens Actuators B Chem. 2016;224:217\u201324. https:\/\/doi.org\/10.1016\/j.snb.2015.09.034.","journal-title":"Sens Actuators B Chem"},{"issue":"1","key":"2074_CR83","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/bit.25007","volume":"111","author":"D Park","year":"2014","unstructured":"Park D, et al. Motility analysis of bacteria-based microrobot (bacteriobot) using chemical gradient microchamber. Biotechnol Bioeng. 2014;111(1):134\u201343. https:\/\/doi.org\/10.1002\/bit.25007.","journal-title":"Biotechnol Bioeng"},{"issue":"6","key":"2074_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc7127","volume":"12","author":"AS Cross","year":"2008","unstructured":"Cross AS. What is a virulence factor? J Crit Care. 2008;12(6):1\u20132. https:\/\/doi.org\/10.1186\/cc7127.","journal-title":"J Crit Care"},{"issue":"S1","key":"2074_CR85","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.2166\/wh.2009.036","volume":"7","author":"A Casadevall","year":"2009","unstructured":"Casadevall A, Pirofski L-A. Virulence factors and their mechanisms of action: the view from a damage\u2013response framework. J Water Health. 2009;7(S1):S2\u201318. https:\/\/doi.org\/10.2166\/wh.2009.036.","journal-title":"J Water Health"},{"issue":"3","key":"2074_CR86","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/gt.2013.86","volume":"21","author":"C Lee","year":"2014","unstructured":"Lee C, et al. Salmonella induce autophagy in melanoma by the downregulation of AKT\/mTOR pathway. Gene Ther. 2014;21(3):309\u201316. https:\/\/doi.org\/10.1038\/gt.2013.86.","journal-title":"Gene Ther"},{"issue":"2","key":"2074_CR87","doi-asserted-by":"publisher","first-page":"e00254","DOI":"10.1128\/mbio.00254-15","volume":"6","author":"M Frahm","year":"2015","unstructured":"Frahm M, et al. Efficiency of conditionally attenuated Salmonella enterica serovar typhimurium in bacterium-mediated tumor therapy. MBio. 2015;6(2):e00254-e315. https:\/\/doi.org\/10.1128\/mbio.00254-15.","journal-title":"MBio"},{"issue":"12","key":"2074_CR88","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.vaccine.2005.11.031","volume":"24","author":"HS Na","year":"2006","unstructured":"Na HS, et al. Immune response induced by Salmonella typhimurium defective in ppGpp synthesis. Vaccine. 2006;24(12):2027\u201334. https:\/\/doi.org\/10.1016\/j.vaccine.2005.11.031. (Epub 2005 Dec 1).","journal-title":"Vaccine"},{"issue":"6","key":"2074_CR89","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1083\/jcb.200201081","volume":"156","author":"IJ Glomski","year":"2002","unstructured":"Glomski IJ, et al. The Listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. J Cell Biol. 2002;156(6):1029\u201338. https:\/\/doi.org\/10.1083\/jcb.200201081.","journal-title":"J Cell Biol"},{"issue":"5493","key":"2074_CR90","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1126\/science.290.5493.992","volume":"290","author":"AL Decatur","year":"2000","unstructured":"Decatur AL, Portnoy DA. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science. 2000;290(5493):992\u20135. https:\/\/doi.org\/10.1126\/science.290.5493.992.","journal-title":"Science"},{"issue":"1","key":"2074_CR91","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2958.1993.tb01211.x","volume":"8","author":"A Camilli","year":"1993","unstructured":"Camilli A, Tilney LG, Portnoy DA. Dual roles of plcA in Listeria monocytogenes pathogenesis. Mol Microbiol. 1993;8(1):143\u201357. https:\/\/doi.org\/10.1111\/j.1365-2958.1993.tb01211.x.","journal-title":"Mol Microbiol"},{"issue":"1","key":"2074_CR92","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1128\/IAI.72.1.489-497.2004","volume":"72","author":"AI Bakardjiev","year":"2004","unstructured":"Bakardjiev AI, et al. Listeriosis in the pregnant guinea pig: a model of vertical transmission. Infect Immun. 2004;72(1):489\u201397. https:\/\/doi.org\/10.1128\/IAI.72.1.489-497.2004.","journal-title":"Infect Immun"},{"issue":"5803","key":"2074_CR93","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1126\/science.1130651","volume":"314","author":"I Cheong","year":"2006","unstructured":"Cheong I, et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science. 2006;314(5803):1308\u201311. https:\/\/doi.org\/10.1126\/science.1130651.","journal-title":"Science"},{"issue":"2","key":"2074_CR94","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/1097-0142(197202)29:2%3C431::AID-CNCR2820290226%3E3.0.CO;2-Z","volume":"29","author":"A Chagnon","year":"1972","unstructured":"Chagnon A, et al. Cytotoxicity and reduction of animal cell growth by clostridium M-55 spores and their extracts. Cancer. 1972;29(2):431\u20134. https:\/\/doi.org\/10.1002\/1097-0142(197202)29:2%3C431::AID-CNCR2820290226%3E3.0.CO;2-Z.","journal-title":"Cancer"},{"key":"2074_CR95","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8451728","author":"S Felgner","year":"2016","unstructured":"Felgner S, et al. Bacteria in cancer therapy: renaissance of an old concept. Int J microbiol. 2016. https:\/\/doi.org\/10.1155\/2016\/8451728.","journal-title":"Int J microbiol"},{"issue":"10","key":"2074_CR96","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrmicro2218","volume":"7","author":"R Fronzes","year":"2009","unstructured":"Fronzes R, Christie PJ, Waksman G. The structural biology of type IV secretion systems. Nat Rev Microbiol. 2009;7(10):703\u201314. https:\/\/doi.org\/10.1038\/nrmicro2218.","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"2074_CR97","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1128\/JB.00901-15","volume":"198","author":"MM Farley","year":"2016","unstructured":"Farley MM, et al. Minicells, back in fashion. J Bacteriol. 2016;198(8):1186\u201395. https:\/\/doi.org\/10.1128\/JB.00901-15.","journal-title":"J Bacteriol"},{"key":"2074_CR98","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.cgt.7701109","volume":"15","author":"J Fensterle","year":"2008","unstructured":"Fensterle J, Bergmann B, Yone C, et al. Cancer immunotherapy based on recombinant Salmonella enterica serovar typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther. 2008;15:85\u201393. https:\/\/doi.org\/10.1038\/sj.cgt.7701109.","journal-title":"Cancer Gene Ther"},{"key":"2074_CR99","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00262-010-0950-x","volume":"60","author":"E Roider","year":"2011","unstructured":"Roider E, Jellbauer S, K\u00f6hn B, et al. Invasion and destruction of a murine fibrosarcoma by Salmonella-induced effector CD8 T cells as a therapeutic intervention against cancer. Cancer Immunol Immunother. 2011;60:371\u201380. https:\/\/doi.org\/10.1007\/s00262-010-0950-x.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2074_CR100","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ymthe.2006.06.011","volume":"14","author":"O Epaulard","year":"2006","unstructured":"Epaulard O, et al. Anti-tumor immunotherapy via antigen delivery from a live attenuated genetically engineered Pseudomonas aeruginosa type III secretion system-based vector. Mol Ther. 2006;14(5):656\u201361. https:\/\/doi.org\/10.1016\/j.ymthe.2006.06.011.","journal-title":"Mol Ther"},{"key":"2074_CR101","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ymben.2022.08.006","volume":"73","author":"S-J Kim","year":"2022","unstructured":"Kim S-J, Chang W, Oh M-K. Escherichia coli minicells with targeted enzymes as bioreactors for producing toxic compounds. Metab Eng. 2022;73:214\u201324. https:\/\/doi.org\/10.1016\/j.ymben.2022.08.006.","journal-title":"Metab Eng"},{"issue":"7","key":"2074_CR102","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.molmed.2012.05.006","volume":"18","author":"AW Paton","year":"2012","unstructured":"Paton AW, Morona R, Paton JC. Bioengineered microbes in disease therapy. Trends Mol Med. 2012;18(7):417\u201325. https:\/\/doi.org\/10.1016\/j.molmed.2012.05.006.","journal-title":"Trends Mol Med"},{"issue":"3","key":"2074_CR103","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1462-5822.2002.00184.x","volume":"4","author":"C Grillot-Courvalin","year":"2002","unstructured":"Grillot-Courvalin C, Goussard S, Courvalin P. Wild-type intracellular bacteria deliver DNA into mammalian cells. Cell Microbiol. 2002;4(3):177\u201386. https:\/\/doi.org\/10.1046\/j.1462-5822.2002.00184.x.","journal-title":"Cell Microbiol"},{"issue":"5","key":"2074_CR104","doi-asserted-by":"publisher","first-page":"e01220","DOI":"10.1128\/mbio.01220-16","volume":"7","author":"S Felgner","year":"2016","unstructured":"Felgner S, et al. aroA-deficient Salmonella enterica serovar typhimurium is more than a metabolically attenuated mutant. MBio. 2016;7(5):e01220-e1316. https:\/\/doi.org\/10.1128\/mbio.01220-16.","journal-title":"MBio"},{"issue":"5","key":"2074_CR105","doi-asserted-by":"publisher","first-page":"e3015","DOI":"10.1002\/jgm.3015","volume":"20","author":"SL Ginn","year":"2018","unstructured":"Ginn SL, et al. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018;20(5):e3015. https:\/\/doi.org\/10.1002\/jgm.3015.","journal-title":"J Gene Med"},{"issue":"3","key":"2074_CR106","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/MRM.0000000000000005","volume":"25","author":"S Zhang","year":"2014","unstructured":"Zhang S, et al. Role of nontoxigenic Clostridium novyi in solid tumor therapy. Rev Med Microbiol. 2014;25(3):71\u20136. https:\/\/doi.org\/10.1097\/MRM.0000000000000005.","journal-title":"Rev Med Microbiol"},{"issue":"12","key":"2074_CR107","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41568-018-0070-z","volume":"18","author":"S Zhou","year":"2018","unstructured":"Zhou S, et al. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018;18(12):727\u201343. https:\/\/doi.org\/10.1038\/s41568-018-0070-z.","journal-title":"Nat Rev Cancer"},{"key":"2074_CR108","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1538\/expanim.16-0033","volume":"65","author":"X Liu","year":"2016","unstructured":"Liu X, et al. Radiotherapy combined with an engineered of Salmonella typhimurium inhibits tumor growth in a mouse model of colon cancer. Exp Anim. 2016;65:413\u20138. https:\/\/doi.org\/10.1538\/expanim.16-0033.","journal-title":"Exp Anim"},{"issue":"5","key":"2074_CR109","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/1751-7915.12787","volume":"10","author":"S Felgner","year":"2017","unstructured":"Felgner S, et al. Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. Microb Biotechnol. 2017;10(5):1074\u20138. https:\/\/doi.org\/10.1111\/1751-7915.12787.","journal-title":"Microb Biotechnol"},{"issue":"4","key":"2074_CR110","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/sj.cgt.7700303","volume":"8","author":"J Theys","year":"2001","unstructured":"Theys J, et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther. 2001;8(4):294\u20137. https:\/\/doi.org\/10.1038\/sj.cgt.7700303.","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"2074_CR111","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/jcp.25859","volume":"233","author":"R Jahanban-Esfahlan","year":"2018","unstructured":"Jahanban-Esfahlan R, et al. Modulating tumor hypoxia by nanomedicine for effective cancer therapy. J Cell Physiol. 2018;233(3):2019\u201331. https:\/\/doi.org\/10.1002\/jcp.25859.","journal-title":"J Cell Physiol"},{"issue":"7","key":"2074_CR112","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1158\/2159-8290.CD-11-0201","volume":"2","author":"K Flentie","year":"2012","unstructured":"Flentie K, et al. A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in salmonella for conditional bacterial-based tumor therapycancer cell-induced transcriptional response of Salmonella. Cancer Discov. 2012;2(7):624\u201337. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0201.","journal-title":"Cancer Discov"},{"issue":"5","key":"2074_CR113","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4161\/bioe.21130","volume":"3","author":"BS Avner","year":"2012","unstructured":"Avner BS, Fialho AM, Chakrabarty AM. Overcoming drug resistance in multi-drug resistant cancers and microorganisms: a conceptual framework. Bioengineered. 2012;3(5):262\u201370. https:\/\/doi.org\/10.4161\/bioe.21130.","journal-title":"Bioengineered"},{"key":"2074_CR114","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/978-1-0716-1811-0_45","volume":"2394","author":"S Naffouje","year":"2022","unstructured":"Naffouje S, Goto M, Ryoo I, Green A, Das Gupta TK, Yamada T. A Method of tumor in vivo imaging with a new peptide-based fluorescent probe. Methods Mol Biol. 2022;2394:857\u201365. https:\/\/doi.org\/10.1007\/978-1-0716-1811-0_45.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"2074_CR115","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/bjc.2013.74","volume":"108","author":"M Warso","year":"2013","unstructured":"Warso M, et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer. 2013;108(5):1061\u201370. https:\/\/doi.org\/10.1038\/bjc.2013.74.","journal-title":"Br J Cancer"},{"issue":"13","key":"2074_CR116","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.4161\/cbt.21958","volume":"13","author":"AM Fialho","year":"2012","unstructured":"Fialho AM, Chakrabarty AM. Patent controversies and court cases: cancer diagnosis, therapy and prevention. Cancer Biol Ther. 2012;13(13):1229\u201334. https:\/\/doi.org\/10.4161\/cbt.21958.","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"2074_CR117","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/neuonc\/now047","volume":"18","author":"RR Lulla","year":"2016","unstructured":"Lulla RR, et al. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2016;18(9):1319\u201325. https:\/\/doi.org\/10.1093\/neuonc\/now047.","journal-title":"Neuro Oncol"},{"issue":"7","key":"2074_CR118","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1517\/14712598.2015.1044433","volume":"15","author":"TD de Gruijl","year":"2015","unstructured":"de Gruijl TD, Janssen AB, van Beusechem VW. Arming oncolytic viruses to leverage antitumor immunity. Expert Opin Biol Ther. 2015;15(7):959\u201371. https:\/\/doi.org\/10.1517\/14712598.2015.1044433.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"2074_CR119","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"SE Lawler","year":"2017","unstructured":"Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3(6):841\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2064.","journal-title":"JAMA Oncol"},{"issue":"7","key":"2074_CR120","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658\u201370. https:\/\/doi.org\/10.1038\/nbt.2287.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2074_CR121","first-page":"211","volume":"30","author":"A Desjardins","year":"2016","unstructured":"Desjardins A, Vlahovic G, Friedman HS. Vaccine therapy, oncolytic viruses, and gliomas. Oncology (Williston Park). 2016;30(3):211\u20138.","journal-title":"Oncology (Williston Park)"},{"key":"2074_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.03.004","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015. https:\/\/doi.org\/10.1016\/j.semcancer.2015.03.004.","journal-title":"Semin Cancer Biol"},{"key":"2074_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","volume":"39","author":"DH Munn","year":"2016","unstructured":"Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Current Opin Immunol. 2016;39:1\u20136. https:\/\/doi.org\/10.1016\/j.coi.2015.10.009.","journal-title":"Current Opin Immunol"},{"issue":"17","key":"2074_CR124","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974. https:\/\/doi.org\/10.1200\/JCO.2014.59.4358.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2074_CR125","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1172\/JCI80006","volume":"125","author":"S Ugel","year":"2015","unstructured":"Ugel S, et al. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin investig. 2015;125(9):3365\u201376.","journal-title":"J Clin investig"},{"key":"2074_CR126","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3389\/fimmu.2018.02103","volume":"9","author":"A Rosewell Shaw","year":"2018","unstructured":"Rosewell Shaw A, Suzuki M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment. Front Immunol. 2018;9:2103. https:\/\/doi.org\/10.3389\/fimmu.2018.02103.","journal-title":"Front Immunol"},{"issue":"11","key":"2074_CR127","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1172\/JCI32727","volume":"117","author":"SH Thorne","year":"2007","unstructured":"Thorne SH, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Investig. 2007;117(11):3350\u20138.","journal-title":"J Clin Investig"},{"key":"2074_CR128","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fonc.2020.00475","volume":"10","author":"L Li","year":"2020","unstructured":"Li L, et al. Delivery and biosafety of oncolytic virotherapy. Front Oncol. 2020;10:475. https:\/\/doi.org\/10.3389\/fonc.2020.00475.","journal-title":"Front Oncol"},{"issue":"9","key":"2074_CR129","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362. https:\/\/doi.org\/10.1038\/nrd4663.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2074_CR130","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","volume":"2","author":"EA Chiocca","year":"2014","unstructured":"Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295\u2013300. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0015.","journal-title":"Cancer Immunol Res"},{"key":"2074_CR131","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.3389\/fimmu.2019.01848","volume":"10","author":"A Marchini","year":"2019","unstructured":"Marchini A, et al. Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study. Front Immunol. 2019;10:1848. https:\/\/doi.org\/10.3389\/fimmu.2019.01848.","journal-title":"Front Immunol"},{"issue":"1","key":"2074_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-019-0133-7","volume":"5","author":"ME Gatti-Mays","year":"2019","unstructured":"Gatti-Mays ME, et al. If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer. 2019;5(1):1\u201313. https:\/\/doi.org\/10.1038\/s41523-019-0133-7.","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"2074_CR133","doi-asserted-by":"publisher","first-page":"e12441","DOI":"10.1111\/cpr.12441","volume":"51","author":"J Shen","year":"2018","unstructured":"Shen J, et al. Anti-cancer therapy with TNF \u03b1 and IFN \u03b3: a comprehensive review. Cell Prolif. 2018;51(4):e12441. https:\/\/doi.org\/10.1111\/cpr.12441.","journal-title":"Cell Prolif"},{"issue":"1","key":"2074_CR134","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5483\/BMBRep.2021.54.1.257","volume":"54","author":"J-H Kim","year":"2021","unstructured":"Kim J-H, Lee K-J, Lee S-W. Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7. BMB Rep. 2021;54(1):21. https:\/\/doi.org\/10.5483\/BMBRep.2021.54.1.257.","journal-title":"BMB Rep"},{"issue":"1","key":"2074_CR135","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/mt.2015.156","volume":"24","author":"K Rajani","year":"2016","unstructured":"Rajani K, et al. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther. 2016;24(1):166\u201374. https:\/\/doi.org\/10.1038\/mt.2015.156.","journal-title":"Mol Ther"},{"issue":"226","key":"2074_CR136","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin D, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6(226):226ra32. https:\/\/doi.org\/10.1126\/scitranslmed.3008095.","journal-title":"Sci Transl Med."},{"issue":"7","key":"2074_CR137","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/mt.2011.71","volume":"19","author":"R Khare","year":"2011","unstructured":"Khare R, et al. Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther. 2011;19(7):1254\u201362. https:\/\/doi.org\/10.1038\/mt.2011.71.","journal-title":"Mol Ther"},{"issue":"13","key":"2074_CR138","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.jmb.2018.04.039","volume":"430","author":"L Lasswitz","year":"2018","unstructured":"Lasswitz L, et al. Glycomics and proteomics approaches to investigate early adenovirus\u2013host cell interactions. J Mol Biol. 2018;430(13):1863\u201382. https:\/\/doi.org\/10.1016\/j.jmb.2018.04.039.","journal-title":"J Mol Biol"},{"issue":"11","key":"2074_CR139","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.3390\/v7112923","volume":"7","author":"H Uusi-Kerttula","year":"2015","unstructured":"Uusi-Kerttula H, et al. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses. 2015;7(11):6009\u201342. https:\/\/doi.org\/10.3390\/v7112923.","journal-title":"Viruses"},{"issue":"4","key":"2074_CR140","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/hum.2014.001","volume":"25","author":"R Hendrickx","year":"2014","unstructured":"Hendrickx R, et al. Innate immunity to adenovirus. Human Gene Ther. 2014;25(4):265\u201384. https:\/\/doi.org\/10.1089\/hum.2014.001.","journal-title":"Human Gene Ther"},{"issue":"7","key":"2074_CR141","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/ijms18071479","volume":"18","author":"H Tazawa","year":"2017","unstructured":"Tazawa H, et al. Impact of autophagy in oncolytic adenoviral therapy for cancer. Int J Mol Sci. 2017;18(7):1479. https:\/\/doi.org\/10.3390\/ijms18071479.","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"2074_CR142","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.virol.2011.04.017","volume":"416","author":"H Rodriguez-Rocha","year":"2011","unstructured":"Rodriguez-Rocha H, et al. Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology. 2011;416(1\u20132):9\u201315. https:\/\/doi.org\/10.1016\/j.virol.2011.04.017.","journal-title":"Virology"},{"issue":"11","key":"2074_CR143","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/v9110313","volume":"9","author":"C Ros","year":"2017","unstructured":"Ros C, et al. Protoparvovirus cell entry. Viruses. 2017;9(11):313. https:\/\/doi.org\/10.3390\/v9110313.","journal-title":"Viruses"},{"issue":"1","key":"2074_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-014-0223-y","volume":"12","author":"A Marchini","year":"2015","unstructured":"Marchini A, et al. Oncolytic parvoviruses: from basic virology to clinical applications. Virol J. 2015;12(1):1\u201316. https:\/\/doi.org\/10.1186\/s12985-014-0223-y.","journal-title":"Virol J"},{"issue":"11","key":"2074_CR145","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","volume":"94","author":"GL Smith","year":"2013","unstructured":"Smith GL, et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol. 2013;94(11):2367\u201392. https:\/\/doi.org\/10.1099\/vir.0.055921-0.","journal-title":"J Gen Virol"},{"issue":"5","key":"2074_CR146","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","volume":"25","author":"HJ Chon","year":"2019","unstructured":"Chon HJ, et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade potentiation of immunotherapy by oncolytic vaccinia virus. Clin Cancer Res. 2019;25(5):1612\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1932.","journal-title":"Clin Cancer Res"},{"key":"2074_CR147","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.2147\/OTT.S249816","volume":"13","author":"L Deng","year":"2020","unstructured":"Deng L, et al. An oncolytic vaccinia virus armed with GM-CSF and IL-24 double genes for cancer targeted therapy. OncoTargets Ther. 2020;13:3535. https:\/\/doi.org\/10.2147\/OTT.S249816.","journal-title":"OncoTargets Ther."},{"issue":"11","key":"2074_CR148","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1128\/JCM.01531-13","volume":"51","author":"A Steyer","year":"2013","unstructured":"Steyer A, et al. High similarity of novel orthoreovirus detected in a child hospitalized with acute gastroenteritis to mammalian orthoreoviruses found in bats in Europe. J clin Microbiol. 2013;51(11):3818\u201325. https:\/\/doi.org\/10.1128\/JCM.01531-13.","journal-title":"J clin Microbiol"},{"issue":"4","key":"2074_CR149","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.meegid.2009.01.011","volume":"9","author":"JM Day","year":"2009","unstructured":"Day JM. The diversity of the orthoreoviruses: molecular taxonomy and phylogentic divides. Infect Genet and Evol. 2009;9(4):390\u2013400. https:\/\/doi.org\/10.1016\/j.meegid.2009.01.011.","journal-title":"Infect Genet and Evol"},{"key":"2074_CR150","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/oxfordjournals.aje.a120109","volume":"71","author":"L Rosen","year":"1960","unstructured":"Rosen L, Hovis JF, Mastrota FM, Bell JA, Huebner R. Observations on a newly recognized virus (Abney) of the reovirus family. Am J Epidemiol. 1960;71:258\u201365. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a120109.","journal-title":"Am J Epidemiol"},{"issue":"3386","key":"2074_CR151","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.130.3386.1387","volume":"130","author":"AB Sabin","year":"1959","unstructured":"Sabin AB. Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science. 1959;130(3386):1387\u20139. https:\/\/doi.org\/10.1126\/science.130.3386.1387.","journal-title":"Science"},{"issue":"4","key":"2074_CR152","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/BF01314776","volume":"54","author":"G Hashiro","year":"1977","unstructured":"Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol. 1977;54(4):307\u201315. https:\/\/doi.org\/10.1007\/BF01314776.","journal-title":"Arch Virol"},{"issue":"1","key":"2074_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-018-0281-9","volume":"19","author":"W Ma","year":"2018","unstructured":"Ma W, He H, Wang H. Oncolytic herpes simplex virus and immunotherapy. BMC immunol. 2018;19(1):1\u201311. https:\/\/doi.org\/10.1186\/s12865-018-0281-9.","journal-title":"BMC immunol"},{"issue":"2","key":"2074_CR154","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.virol.2012.08.043","volume":"433","author":"G Watson","year":"2012","unstructured":"Watson G, et al. Sequence and comparative analysis of the genome of HSV-1 strain McKrae. Virology. 2012;433(2):528\u201337. https:\/\/doi.org\/10.1016\/j.virol.2012.08.043.","journal-title":"Virology"},{"key":"2074_CR155","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-981-10-7230-7_4","volume":"1045","author":"D Watanabe","year":"2018","unstructured":"Watanabe D, Goshima F. Oncolytic virotherapy by HSV. Adv Exp Med Biol. 2018;1045:63\u201384. https:\/\/doi.org\/10.1007\/978-981-10-7230-7_4.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"2074_CR156","first-page":"1693","volume":"7","author":"R Tanaka","year":"2017","unstructured":"Tanaka R, et al. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model. Am J Cancer Res. 2017;7(8):1693.","journal-title":"Am J Cancer Res"},{"issue":"1 Pt 1","key":"2074_CR157","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1158\/1078-0432.ccr-0690-3","volume":"10","author":"DR Shafren","year":"2004","unstructured":"Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P, Barry RD. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res. 2004;10(1 Pt 1):53\u201360. https:\/\/doi.org\/10.1158\/1078-0432.ccr-0690-3.","journal-title":"Clin Cancer Res"},{"key":"2074_CR158","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.tps3128","author":"RHI Andtbacka","year":"2013","unstructured":"Andtbacka RHI, et al. CALM study: a phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma. Am Soc Clin Oncol. 2013. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.tps3128.","journal-title":"Am Soc Clin Oncol"},{"issue":"7","key":"2074_CR159","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3390\/nu11071514","volume":"11","author":"P De Cicco","year":"2019","unstructured":"De Cicco P, Catani MV, Gasperi V, Sibilano M, Quaglietta M, Savini I. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence. Nutrients. 2019;11(7):1514. https:\/\/doi.org\/10.3390\/nu11071514.","journal-title":"Nutrients"},{"key":"2074_CR160","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/CLEP.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong N, et al. A systematic review of the international prevalence of BRCA mutation in breast cancer. J Clin Epidemiol. 2019;11:543. https:\/\/doi.org\/10.2147\/CLEP.S206949.","journal-title":"J Clin Epidemiol"},{"key":"2074_CR161","doi-asserted-by":"crossref","unstructured":"Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, et al. Health and racial disparity in breast cancer. In: Breast cancer metastasis and drug resistance: challenges and progress, 2019, pp. 31\u201349.","DOI":"10.1007\/978-3-030-20301-6_3"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02074-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T21:21:33Z","timestamp":1687900893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02074-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,18]]},"references-count":161,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2074"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02074-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,18]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"207"}}